Health Care

Sarepta Therapeutics Inc (SRPT) Rating Increased to Buy at SunTrust Banks, Inc

Granite Point Capital Management, L.p. augmented its investment by buying 39,850 shares an increase of 170.5% in the quarter. Kaye now owns $2,151,311 of the stock according to the SEC filing.

A number of other research firms have also recently weighed in on SRPT.

Sarepta Therapeutics (NASDAQ:SRPT) traded down 4.07% during mid-day trading on Wednesday, reaching $34.40. About 1.82M shares traded. Finally, Edge Wealth Management LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at about $175,000. As of quarter end Point72 Asset Management, L.p. had acquired 1,222,106 shares growing its position 152.1%. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Syndax Pharmaceuticals Inc, and Catabasis Pharmaceuticals. Wells Fargo & Company MN now owns 108,477 shares of the biotechnology company's stock worth $3,657,000 after acquiring an additional 23,767 shares during the last quarter. Voya Investment Management LLC boosted its position in Sarepta Therapeutics by 2,786.1% during the second quarter. Shamim Ruff, SVP, Regulatory Affairs & Qual sold $395,950 worth of shares at a price of $43.33 on July 21st. $24.50's average target is 19.45% above currents $20.51 stock price. Following the sale, the senior vice president now owns 22,793 shares of the company's stock, valued at $934,513. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram purchased 47,058 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. The disclosure for this sale can be found here. They now have $30.97 price target on the biotechnology company's stock, up from their previous price target of $30.00.

Analysts await Donnelley Financial Solutions Inc (NYSE:DFIN) to report earnings on November, 1. Credit Suisse Group set a $64.00 target price on shares of Sarepta Therapeutics and gave the stock a buy rating in a research note on Tuesday, July 18th. Finally, Zacks Investment Research downgraded shares of Sarepta Therapeutics from a buy rating to a hold rating in a report on Monday, July 17th. Amer Century Cos holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 37,652 shares. William Blair maintained the stock with "Buy" rating in Wednesday, August 26 report. Needham & Company LLC reaffirmed a positive rating and set a $81.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, January 12th. The forecast of 13 surveyed investment analysts covering the stock advises investors to Buy stake in the company. The stock has a consensus rating of "Buy" and an average target price of $62.31. The company rocked its 52-Week High of $63.73 and touched its 52-Week Low of $26.26. (SRPT) opened at 46.73 on Thursday. The volume of 1.22 Million shares climbed down over an trading activity of 2.62 Million shares. The firm has a 50-day moving average of $31.26 and a 200 day moving average of $33.41. The company has market cap of $511,133.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, July 19th. The company beat the analyst EPS Estimate with the difference of $0.14. The firm had revenue of $35.01 million during the quarter, compared to analysts' expectations of $22.52 million. The firm's revenue was up 350000.0% compared to the same quarter past year. With an institutional ownership near 40.2%, it carries an earnings per share ratio of 1.28. Sarepta Therapeutics, Inc. (SRPT) average trading volume of 2,577,140 during the past month is 9.2% above its average volume over the past year, indicating that investors have been more active than usual in the stock in recent times. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) earned "Overweight" rating by Piper Jaffray on Monday, August 24. First Allied Advisory Services has invested 0.01% in Sarepta Therapeutics Inc (NASDAQ:SRPT). If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of global trademark and copyright legislation.

Sarepta Therapeutics, Inc.is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).



Like this

loading...
loading...

Latest


25 September 2017
US Kills 17 IS Militants in Libya
Under the deal made in December 2015, The UN-backed Government of National Accord was established. The U.S. military says 17 Islamic State militants were killed in airstrikes on Libya.

25 September 2017
Gov. Scott deleted nursing home voicemails ahead of deaths
Florida Department of Health Chief of Staff Alexis Lambert reportedly returned the call two hours later. State health administrators allegedly returned the call later the same day, according to the report.

25 September 2017
1st woman graduates Marine infantry officer course today
Since then, four female Marine officers have unsuccessfully attempted to go through the infantry course. The course is a prerequisite for ground intelligence officers and considered one of the hardest.

25 September 2017
Defying Trump, Iran says will boost missile capabilities
The missile is believed to have a range of about 1,250 miles, making it capable of reaching a large portion of the Middle East. As a result, Washington has tightened sanctions on Iran - rather than loosen them, as the JCPOA was meant to accomplish.

25 September 2017
This Durga Puja celebrations, Meghalaya adopts Modi's 'swachh' mantra
As per the Swachh Survekshan 2017, Shillong ranks 276th out of 434 cities and towns across the country. However, the chief minister asked the organisers to replace the model with another one.

25 September 2017
CBS releases new Young Sheldon promo ahead of tonight's premiere
Plus, he adds, "I think we dealt with [Amy's] answer in a way that felt the most real and natural to the character", he adds. The previous season ended with Sheldon getting down on one knee asking Amy to be his wife.

25 September 2017
Alejandro Villanueva's jersey becomes an overnight best-seller after he stands for anthem
He made it into professional football via a regional showcase when the Eagles signed him back in 2014 to play defensive end. He is the recipient of the Bronze Star medal for valor and the Bronze Star medal for overseas service.

25 September 2017
Trump Issues New Travel Restrictions As Ban Expires
After five months of litigation before the courts, an amended version of the decree came into force on 29 June. The move means the travel ban is no longer restricted to counties with majority Muslim populations.

25 September 2017
No Home Will be Without Power, Says PM
The Centre said the total purview of the scheme is Rs 16,320 crore, and the government's budgetary assistance is Rs 12,320 crore. The scheme will cover all rural families after electrification of all villages by December end, this year.

25 September 2017
PSG offer Cavani €1m a year... to let Neymar take the penalties
Paris Saint-Germain have denied they offered Edinson Cavani a €1million incentive to allow Neymar to take penalties for the club. PSG's star duo had argued on the pitch over who would take a penalty against Lyon in the Ligue 1 clash on 17 September.